MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor
MIAMI, March 21, 2024 /PRNewswire/ -- MIRA Pharmaceuticals Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), an innovative pre-clinical-stage pharmaceutical company focused on the development of novel treatments for neurologic and neuropsychiatric disorders, proudly announces the appointment of distinguished pharmaceutical executive Dr. Itzchak Angel as its new Chief Scientific Advisor.
- Dr. Angel brings over 40 years of preclinical, clinical and regulatory acumen to MIRA.
- He has significantly contributed to the research, development and regulatory approval of groundbreaking medications over his remarkable career.
- Additionally, his activities contributed to the development and marketing of Mizollen (mizolastine), Xatral (alfuzosin) and Ambien (zolpidem).
- "We are truly honored to have Dr. Angel on our team," stated Erez Aminov, Chairman & CEO of MIRA.